ArticleCancer research communications2025

Preclinical Activity of the Type II RAF Inhibitor Tovorafenib in Tumor Models Harboring Either a BRAF Fusion or an NF1 Loss-of-Function Mutation.

Shubhra Rastogi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.